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Purpose: Erythromycin-resistant -hemolytic streptococci β
(BHS) has recently emerged and quickly spread between and
within countries throughout the world. In this study, we evaluate
the antimicrobial susceptibility patterns and erythromycin
resistance mechanisms of BHS during 2003-2004. Materials and
Methods: The MICs of seven antimicrobials were determined
for 204 clinical isolates of BHS from 2003 to 2004. Resistance
mechanisms of erythromycin-resistant BHS were studied by the
double disk test as well as by polymerase chain reaction (PCR).
Results: Compared with our previous study, resistance among
Streptococcus pyogenes isolates to a variety of drugs decreased
strikingly: from 25.7% to 4.8% in erythromycin; 15.8% to 0%
in clindamycin; and 47.1% to 19.0% in tetracycline. The
prevalent phenotypes and genotypes of macrolide-lincosamide-
streptograminB (MLSB) resistance in Streptococcus pyogenes
isolates have been changed from the constitutive MLSB
phenotype carrying erm(B) to the M phenotype with mef(A)
gene. In contrast with Streptococcus pyogenes, resistance rates
to erythromycin (36.7%), clindamycin (43.1%), and tetracy-
cline (95.4%) in Streptococcus agalactiae isolates did not show
decreasing trends. Among the Streptococcus dysgalactiae subsp.
equisimilis isolates (Lancefield group C, G), resistance rates to
erythromycin, clindamycin, tetracycline and chloramphenicol
were observed to be 9.4%, 3.1%, 68.8%, and 9.4%, respec-
tively. Conclusion: Continual monitoring of antimicrobial
resistance among large-colony-forming BHS is needed to
provide the medical community with current data regarding the
resistance mechanisms that are most common to their local or
regional environments.
Key Words: -hemolytic streptococci, antibiotic resistance, β
macrolides, erythromycin, Streptococcus agalactiae, Streptoco-
ccus pyogenes
INTRODUCTION
-hemolytic streptococcal (BHS) isolates from β
humans can be subdivided into large-colony and
small-colony (< 0.5 mm in diameter) formers.
Streptococcus pyogenes (Lancefield group A), Strep-
tococcus agalactiae (group B), and Streptococcus
dysgalactiae subsp. equisimilis (group C, G) belong
to large-colony formers.
1 Although large-colony-
forming -hemolytic streptococci (LCF-BHS) are β
still susceptible to -lactams, macrolides or β
lincosamides are recommended as alternative
choices when indicated.
1-3 However, recent studies
have shown that changes in the susceptibility of
LCF-BHS to erythromycin and clindamycin have
been substantial, although differences in resis-
tance rates to these agents exist according to
geographical variation and investigators.
4-8 The
high transmissibility of LCF-BHS, including
resistant clones and the association of increased
macrolide usage, may play a significant role in the
variable resistance rates that have been reported
during the last decade.
9-11
In Korea, resistant bacteria are more prevalent
than in other industrialized countries, and their
presence suggests a high level of antimicrobial
selective pressure as well as the nosocomial
spread of resistant bacteria.
12 In response to this
public health problem, the Korean government
instituted a new health policy, ‘the separation of
prescribing and dispensing (SPD) of medications’,
on July 1, 2000. The purpose of this policy was to
provide greater differentiation between the roles of
physicians and pharmacists than had historically
existed in South Korea. In our previous study,
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however, the resistance rates to erythromycin and
clindamycin among Streptococcus pyogenes, Streptoco-
ccus agalactiae, and group C streptococci isolates
were still high during the period of 2001-2002.
Two major mechanisms account for erythro-
mycin resistance in many gram-positive bacteria:
target site modification and active efflux. Target
site modification is mediated by erythromycin
resistance methylase that is encoded by erm class
genes. Methylases cause a conformational change
in the prokaryocytic ribosome, leading to reduced
binding of macrolide-lincosamide-streptograminB
(MLSB) antibiotics to the target site in the 50S
ribosomal subunit. The phenotype expression of
MLSB resistance in streptococci can be either
constitutive or inducible. Macrolide efflux, which
is effected by a membrane protein encoded by the
mef class genes, has recently emerged among
Streptococcus pyogenes and Streptococcus pneumo-
niae in many countries.
14 It has been well docu-
mented that the frequency of MLSB resistance
phenotypes among streptococci varies consider-
ably between countries.
14
The objectives of the present study were to
investigate the incidence and trend in suscepti-
bility among the LCF-BHS isolated from clinical
specimens in a Korean hospital and to clarify the
phenotypes and genotypes of erythromycin-
resistant LCF-BHS. We also explored the correla-
tion between serotypes and genotypes of erythro-
mycin-resistant Streptococcus agalactiae.
MATERIALS AND METHODS
A total of 204 strains of LCF-BHS were obtained
from various clinical specimens between January
2003 and December 2004 at Wonju Christian
Hospital in Korea. Multiple isolates from the same
patient were avoided. The isolates were identified
by standard criteria on the basis of hemolytic
patterns on 5% sheep blood agar, colony mor-
phology, Gram stain, catalase reaction, Streptex
latex agglutination assay (Murex Biotech Limited,
Dartford, England), and API Rapid ID32 STREP
system (bioMérieux, Marcy l’Etoile, France).
The strains were stored in thioglycollate broth
with 20% glycerol at -70℃ until analyzed. The
frozen isolates of LCF-BHS were thawed,
inoculated onto a 5% sheep blood agar plate and
incubated at 35℃ overnight. Pure isolates of LCF-
BHS obtained from three consecutive subcultures
were tested for susceptibility and polymerase
chain reaction (PCR).
Susceptibility to penicillin G, erythromycin,
clindamycin, tetracycline, ceftriaxone, chloram-
phenicol (Sigma Chemical Co, St. Louis, MO,
USA) and vancomycin (Daewoong Lilly, Seoul,
Korea) was tested by the agar dilution method
according to the recommendations of the Clinical
and Laboratory Standards Institute.
15 The
Streptococcus pneumoniae ATCC 49619 strain was
simultaneously tested to monitor the accuracy of
minimal inhibitory concentrations of LCF-BHS.
The resistance phenotypes of erythromycin-
resistant isolates were determined by the double-
disc test with erythromycin (15 g) and clinda μ -
mycin (2 g) disks. μ
13
The genomic DNA extractions were carried out
with the Easy-DNA kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instruc-
tions. The presence of erm and mef class genes was
determined by PCR amplification using pre-
viously described primers specific for erm(A),
erm(B), erm(C), erm(TR), and mef(A).
13
GBS serotypes Ia, Ib, and II~VIII were deter-
mined by use of a coagglutination test (ESSUM
Group B Streptococcus Serotyping Test; Bacterum
AB, Umeå, Sweden).
13
RESULTS
The overall non-susceptible (intermediate and
resistance) rates of LCF-BHS were 67.6% to
tetracycline, 23.5% to clindamycin, 22.5% to
erythromycin and 9.8% to chloramphenicol,
whereas all isolates were susceptible to penicillin
G, ceftriaxone, and vancomycin. Resistant rates to
tetracycline, erythromycin, and clindamycin of
Streptococcus agalactiae and Streptococcus pyogenes
isolates were 95.4% versus 19.0%, 36.7% versus
4.8%, and 43.1% versus 0%, respectively. Three
isolates of group C LCF-BHS were susceptible to
all tested antimicrobial agents. Resistant rates to
chloramphenicol, erythromycin, and clindamycin
of group G LCF-BHS were higher than those of
Streptococcus pyogenes (Table 1).Macrolide Resistance Trends in -Hemolytic Streptococci in a Tertiary Korean Hospital β
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Of the 46 erythromycin-resistant LCF-BHS
isolates (Table 2), 37 isolates (80.4%) had the
constitutive macrolide-lincosamide-streptograminB
(cMLSB) phenotype, six isolates (13.0%) had the M
phenotype, and three (6.5%) isolates had the
inducible MLSB (iMLSB) phenotype. Of the 40 ery-
thromycin-resistant Streptococcus agalactiae strains,
the most prevalent gene was erm(B) (92.5%). All
three erythromycin-resistant Streptococcus pyogenes
isolates had mef(A) gene. Four isolates of Strep-
tococcus agalactiae had both of erm(B) and erm(TR)
genes. Three isolates of Streptococcus dysgalactiae
subsp. equisimilis had different resistance genes.
The serotype frequency of 103 Streptococcus
Table 1. Antimicrobial Susceptibilities of Large-Colony-Forming -Hemolytic Streptococci β
Serogroup
(No. of
isolates
tested)
Resistance rate by year
Erythromycin Clindamycin Tetracycline Chloramphenicol
MIC50/90
Mean
(2003/2004)
MIC50/90
Mean
(2003/2004)
MIC50/90
Mean
(2003/2004)
MIC50/90
Mean
(2003/2004)
A (63) 0.06/0.06 4.8
(3.6/5.7)
0.03/0.12 0
(0/0)
1/32 19.0
(35.7/5.7)
4/4 0
(0/0)
B (109) 0.12/256 36.7
(34.1/38.5)
0.25/256 43.1
(34.1/49.2)
32/64 95.4
(93.2/96.9)
4/8 14.6
(15.9/13.8)
C (3) 0.06/0.12 0
(0/0)
0.12/0.25 0
(0/0)
1/2 0
(0/0)
4/4 0
(0/0)
G (29) 0.06/2 10.3
(8.3/11.8)
0.12/0.25 3.4
(0/5.9)
32/64 75.9
(66.7/82.4)
4/8 10.3
(16.7/5.9)
Total
(204)
0.06/256 22.5
(19.8/24.6)
0.12/256 23.5
(17.4/28.0)
32/64 67.6
(68.6/66.9)
4/4 9.8
(10.5/9.3)
MIC, minimal inhibitory concentration.
Table 2. Distributions of Phenotype and Genotype of MLSB Resistance among 46 Isolates of Erythromycin-Resistant
Large-Colony-Forming -Hemolytic Streptococci β
Isolates tested (n) Genotype (n)
Phenotype (n)
DDS Antibiogram
Streptococcus pyogenes (3) mef(A) (3) M (3) EM-R CLI-S (3)
Streptococcus agalactiae (40) erm(B) (33)
erm(B) + erm(TR) (3)
cMLSB (33)
cMLSB (3)
EM-R CLI-R (33)
EM-R CLI-R (3)
mef(A) (2) M (2) EM-R CLI-S (1)
EM-R CLI-R (1)
erm(B) + erm(TR) (1)
erm(TR) (1)
iMLSB (1)
iMLSB (1)
EM-R CLI-R (1)
EM-R CLI-R (1)
Streptococcus dysgalactiae subsp. equisimilis (3) erm(B) (1) cMLSB (1) EM-R CLI-R (1)
mef(A) (1) M (1) EM-R CLI-S (1)
erm(TR) (1) iMLSB (1) EM-R CLI-S (1)
DDS, erythromycin and clindamycin double disk synergy test; MLSB, macrolide-lincosamide-streptograminB; cMLSB, constitutive
resistance to MLSB; M, M phenotype; iMLSB, inducible resistance to MLSB; EM-R, erythromycin-resistant; CLI-S, clindamycin-
susceptible; CLI-R, clindamycin-resistant.Young Uh, et al.
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agalactiae isolates was V (32.0%), III (22.3%), Ia
(15.5%), and Ib (14.6%). The resistance rates to
erythromycin by serotypes were 85% (V), 22%
(III), 13% (Ib), and 0% (Ia) (Table 3).
Among the LCF-BHS isolates, 72 (35.3%) were
from genitourinary specimens, 68 (33.3%) from
wounds, 32 (15.7%) from blood, 18 (8.8%) from
lower respiratory tract specimens, 11 (5.3%) from
throat and 3 (1.5%) from other body fluids.
Streptococcus pyogenes were frequently isolated
from the throat, blood, and wounds, whereas
Streptococcus agalactiae and Streptococcus dysgalac-
tiae subsp. equisimilis were prevalent in geni-
tourinary tract specimens and lower respiratory
tract specimens, respectively (Table 4).
DISCUSSION
Until the 1980s, LCF-BHS were generally con-
sidered uniformly susceptible to erythromycin
and clindamycin, but resistance spread rapidly in
the 1990s. The prevalence of erythromycin-
resistant LCF-BHS has been reported to be
variable and depends on the country, selective
pressure, serogroup, serotype, age, and season.
Compared with our previous study,
13 we
observed that resistance among Streptococcus
pyogenes isolates decreased from 25.7% to 4.8% in
erythromycin, 15.8% to 0% in clindamycin, and
47.1% to 19.0% in tetracycline. In addition, the
prevalent phenotypes and genotypes of MLSB
resistance in Streptococcus pyogenes isolates have
changed from the cMLSB phenotype carrying erm
(B) to the M phenotype with the mef(A) gene. The
determination of antibiotic prescriptions in out-
patient clinics is an important factor to consider
when decreasing resistance rates to commonly
used antimicrobial agents, especially in skin and
upper respiratory infections, are observed.
The isolation rate of Streptococcus pyogenes from
throat specimens was 2.0% (2/102) in our hospital
during the period of 1997-2000.
16 These results
suggested that resistance rates to commonly-used
antimicrobial agents in outpatient clinics and the
distribution of MLSB resistance phenotypes were
Table 3. Rates of Antimicrobial Resistance of Streptococcus agalactiae by Serotypes
Antimicrobials
No. (%) of resistance isolates by serotype
Ia [16]* Ib [15] III [23] IV [1] V [33] VI [1] VII [1] VIII [1] NT [12]
Erythromycin 0 (0) 2 (13) 5 (22) 1 (100) 28 (85) 1 (100) 1 (100) 0 (0) 0 (0)
Clindamycin 1 (6) 3 (20) 10 (44) 1 (100) 29 (88) 1 (100) 1 (100) 0 (0) 0 (0)
Tetracycline 16 (100) 14 (93) 22 (96) 1 (100) 33 (100) 1 (100) 1 (100) 0 (0) 12 (100)
Chloramphenicol 0 (0) 2 (13) 2 (9) 1 (100) 11 (33) 0 (0) 0 (0) 0 (0) 0 (0)
NT, not-typeable.
*The numbers in brackets mean the total No. of Streptococcus agalactiae isolates by serotype.
Table 4. Distribution of Erythromycin-Resistant Large-Colony-Forming -Hemolytic Streptococci according to β
Specimen Type
Species (No. of isolates)
No. of isolates by specimen type (No. of erythromycin-resistant isolates)
Blood Body fluid*
Bronchial
washing
Sputum Throat Urine Cervix
Prostatic
juice
Wound
Streptococcus pyogenes (63) 17 (1) 0 (0) 4 (0) 2 (0) 11 (0) 0 (0) 2 (0) 0 (0) 27 (2)
Streptococcus agalactiae (109) 11 (1) 3 (1) 0 (0) 2 (1) 0 (0) 27 (13) 24 (4) 16 (5) 26 (15)
Streptococcus dysgalactiae subsp.
equisimilis (32)
4 (0) 0 (0) 2 (0) 8 (2) 0 (0) 1 (0) 1 (1) 1 (0) 15 (0)
*Cerebrospinal fluid (2), amniotic fluid (1).Macrolide Resistance Trends in -Hemolytic Streptococci in a Tertiary Korean Hospital β
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partly influenced by selective pressure.
In contrast with Streptococcus pyogenes, resis-
tance rates to erythromycin, clindamycin, and
tetracycline in Streptococcus agalactiae isolates did
not show decreasing trends in this study. The
continued high resistance rates to erythromycin,
clindamycin, and tetracycline are considered
related to the clonal spread of serotype V with a
multi-drug resistance phenotype.
17 The resistance
rates to clindamycin of our serotypes Ib and III
isolates were higher than that of erythromycin,
while the other serotypes were nearly equal in
susceptible rates to erythromycin and clinda-
mycin. Our results show resistance to clindamycin
to be more common than resistance to erythro-
mycin, and similar results have been reported in
Taiwan and New Zealand.
18,19 The distribution of
MLSB resistant genes and the isolation frequency
of serotypes of GBS may be major factors
contributing to the difference between erythro-
mycin and clindamycin resistance in different
countries.
Malbruny et al. have reported that a new LSA
(lincosamide-streptogramin A) phenotype was
noted in erythromycin-susceptible, clindamycin-
resistant Streptococcus agalactiae isolates from New
Zealand, and that III (13/19) and I (5/19) were the
main serotypes of GBS with LSA phenotype.
19
However, in spite of their extensive molecular
studies, the resistance mechanism of LSA in
Streptococcus agalactiae was not elucidated.
The overall resistance rates to erythromycin and
clindamycin in group C and G BHS seemed to be
somewhat lower than those of our previous
results.
13 Streptococcus dysgalactiae subsp. equisimilis
colonizes and causes various infections in hu-
mans.
20,21 Zaoutis et al. reported that three isolates
(group G; 2, group C; 1) of 23 Streptococcus
dysgalactiae subsp. equisimilis were resistant to
erythromycin.
21 Hashikawa et al. documented that
all eleven of the Streptococcus dysgalactiae subsp.
equisimilis strains were sensitive to -lactam anti β -
biotics, vancomycin, and chloramphenicol, whereas
about half of the strains were tetracycline resistant,
and one strain was resistant to erythromycin and
clindamycin harbored erm(B).
22 Our findings were
similar to those of the aforementioned investiga-
tors’ reports.
Continual monitoring of antimicrobial resis-
tance among LCF-BHS is needed to provide the
medical community with current data regarding
the resistance mechanisms that are most common
to their local or regional environments. Addi-
tionally, further epidemiologic studies are needed
to confirm whether or not our susceptibility data
on LCF-BHS are restricted to our geographic area.
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